Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case–control study
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case–control study
Authors
Keywords
-
Journal
Lancet Respiratory Medicine
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2022-04-23
DOI
10.1016/s2213-2600(22)00101-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron
- (2022) Alison Tarke et al. CELL
- Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants
- (2022) Emma K. Accorsi et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study
- (2022) Nicole Wolter et al. LANCET
- Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization
- (2022) Sandile Cele et al. NATURE
- Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa
- (2022) Raquel Viana et al. NATURE
- Homologous and Heterologous Covid-19 Booster Vaccinations
- (2022) Robert L. Atmar et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera
- (2022) Alexander Muik et al. SCIENCE
- Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022
- (2022) Jill M. Ferdinands et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Trends in Disease Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous SARS-CoV-2 High Transmission Periods — United States, December 2020–January 2022
- (2022) A. Danielle Iuliano et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022
- (2022) Mark G. Thompson et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- SARS-CoV-2 Infection and Hospitalization Among Adults Aged ≥18 Years, by Vaccination Status, Before and During SARS-CoV-2 B.1.1.529 (Omicron) Variant Predominance — Los Angeles County, California, November 7, 2021–January 8, 2022
- (2022) Phoebe Danza et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Divergent SARS CoV-2 Omicron-reactive T- and B cell responses in COVID-19 vaccine recipients
- (2022) Corine H. GeurtsvanKessel et al. Science Immunology
- T cell responses to SARS-CoV-2 spike cross-recognize Omicron
- (2022) Roanne Keeton et al. NATURE
- Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant
- (2022) Nick Andrews et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial
- (2021) Xinxue Liu et al. LANCET
- Systems vaccinology of the BNT162b2 mRNA vaccine in humans
- (2021) Prabhu S. Arunachalam et al. NATURE
- SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses
- (2021) Jackson S. Turner et al. NATURE
- Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination
- (2021) Joana Barros-Martins et al. NATURE MEDICINE
- Differential immunogenicity of BNT162b2 or ChAdOx1 vaccines after extended-interval homologous dual vaccination in older people
- (2021) Helen Parry et al. Immunity & Ageing
- Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial
- (2021) Alasdair P S Munro et al. LANCET
- Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study
- (2021) Sara Y Tartof et al. LANCET
- Immunogenicity and efficacy of heterologous ChAdOx1–BNT162b2 vaccination
- (2021) Bruno Pozzetto et al. NATURE
- Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa
- (2021) Shirley Collie et al. NEW ENGLAND JOURNAL OF MEDICINE
- Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection
- (2021) Ital Nemet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Plasma Neutralization of the SARS-CoV-2 Omicron Variant
- (2021) Fabian Schmidt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Track Omicron’s spread with molecular data
- (2021) Lesley Scott et al. SCIENCE
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
- (2020) Fernando P. Polack et al. NEW ENGLAND JOURNAL OF MEDICINE
- A probability model for evaluating the bias and precision of influenza vaccine effectiveness estimates from case-control studies
- (2014) M. HABER et al. EPIDEMIOLOGY AND INFECTION
- The test-negative design: validity, accuracy and precision of vaccine efficacy estimates compared to the gold standard of randomised placebo-controlled clinical trials
- (2013) G De Serres et al. Eurosurveillance
- The test-negative design for estimating influenza vaccine effectiveness
- (2013) Michael L. Jackson et al. VACCINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started